3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). (September 2015) - Patel, S.; Mehren, M. Von; Reed, D.; Agulnik, M.; Kaiser, P.; Charlson, J.; Kraft, A.; Hamm, J.; Karnad, A.; Ryan, C.; Rushing, D.; Meyer, C.; et al.